Takeda Pharmaceuticals International GmbH
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Takeda Pharmaceuticals International GmbH
Will CAR-NK cell therapies overshadow traditional CAR-T options for the treatment of some cancers? While preliminary data for CAR-NKs point to enhanced safety and solid tumor penetration, oncologists and executives discuss the pros and cons of these two approaches to cell therapy.
During Q4, biopharma merger and acquisition value reached $35.7bn and drew in $62.1bn in potential deal value from alliances. Device company M&A values reached $19.2bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $4.8bn.
A new medicine to protect newborns and infants from RSV infection and a new treatment for DLBCL are among a dozen drugs that have been recommended for pan-EU approval.
FDA says warning to VPR Brands could be its first move to reign in sales of nicotine gummies. Statements on brand’s site could indicate sales of nicotine gummies for smoking cessation are on the rise even though the claim isn’t approved.
- Medical Devices
- OTC, Consumer
- Specialty Pharmaceuticals
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.